Agilent Technologies, Inc. $A Shares Sold by Allstate Corp

Key Points

• Allstate Corp has reduced its stake in Agilent Technologies by 26.3%, selling 2,242 shares and now holding a total of 6,277 shares valued at approximately $734,000.
• Other institutional investors have significantly increased their positions in Agilent, with GAMMA Investing LLC boosting its holdings by 15,648.1% during the same period.
• Agilent Technologies reported $1.31 earnings per share for the last quarter, exceeding analyst estimates, alongside a 6.0% increase in revenue year-over-year.

Allstate Corp lessened its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 26.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,277 shares of the medical research company's stock after selling 2,242 shares during the quarter. Allstate Corp's holdings in Agilent Technologies were worth $734,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC increased its holdings in Agilent Technologies by 286.2% during the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock valued at $29,000 after acquiring an additional 186 shares in the last quarter. Sunbelt Securities Inc. grew its position in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock valued at $30,000 after purchasing an additional 192 shares during the last quarter. Stone House Investment Management LLC purchased a new position in shares of Agilent Technologies during the 1st quarter worth approximately $30,000. Opal Wealth Advisors LLC acquired a new position in shares of Agilent Technologies during the 1st quarter worth approximately $31,000. Finally, Wood Tarver Financial Group LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $34,000. 87.41% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Trading Up 0.5%

NYSE A traded up $0.65 during trading hours on Friday, hitting $125.61. 1,076,032 shares of the company's stock were exchanged, compared to its average volume of 1,947,832. The business's 50 day moving average is $118.18 and its 200-day moving average is $116.76. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The firm has a market capitalization of $35.68 billion, a P/E ratio of 29.50, a price-to-earnings-growth ratio of 3.60 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.88%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the prior year, the company posted $1.32 EPS. The company's quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on A. Robert W. Baird increased their target price on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday. Evercore ISI reduced their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research report on Thursday. TD Cowen boosted their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. UBS Group reduced their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $139.25.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is currently owned by corporate insiders.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.